Skip to main content
. 2019 Sep 15;11(9):5546–5559.

Figure 3.

Figure 3

The regulation on claudin5 through JNK by low dose bevacizumab. A. The changes of P-PI3K and P-JNK protein under low-dose bevacizumab (bevacizumab 10 μg/mL) treatment by western-blot in MRMECs, which were consistent with HUVECs. B. Changes of claudin5 and P-JNK protein under JNK inhibitor (SP600125) and/or low-dose bevacizumab treatment by western-blot in HUVECs. SP600125 inhibited both the expression of P-JNK and claudin5. C. mRNA levels of claudin5 following bevacizumab and/or SP600125 treatment, *P < 0.05, **P < 0.005. D. Changes of claudin5 and P-JNK protein under low-dose bevacizumab and/or JNK siRNA treatment by western-blot in HUVECs. JNK siRNA inhibited the expression of JNK, P-JNK and claudin5. E. Claudin5 mRNA expression following bevacizumab and/or JNK siRNA treatment, *P < 0.05, ***P < 0.0005. F. Changes of claudin5 protein following JNK overexpression (jnk-oe) or SP600125. Claudin5 rose and fell together with JNK. G. Changes of claudin5 and P-NK protein under SP600125 and/or low-dose bevacizumab treatment by western-blot in MRMECs, which were consistent with HUVECs. All data were expressed as mean ± SD, and all statistical analyses were performed by one-way ANOVA.